Matinas BioPharma Holdings, Inc. (NYSE: MTNB) has terminated its $50 million at-the-market equity facility with BTIG, removing a key channel for issuing shares into the public market. The decision follows the divestment of MAT2203 and comes as the biotechnology company pursues a proposed merger with GH Power while addressing operating losses, financing requirements and stock-exchange compliance.

Key Highlights

  • Matinas BioPharma Holdings, Inc. (NYSE: MTNB) terminated its $50 million at-the-market equity facility with BTIG effective July 23, 2026.
  • The termination did not result in penalties, termination fees or additional costs for the company.
  • Ending the facility removes a previously available mechanism for issuing shares through the public market.
  • The decision follows the divestment of MAT2203 to privately held Azurity Pharmaceuticals.
  • The company’s proposed merger with privately held GH Power forms part of a broader strategic shift amid operating deficits and listing-compliance challenges.

Matinas BioPharma Terminates BTIG Equity Facility

Matinas BioPharma Holdings, Inc. (NYSE: MTNB) has ended its $50 million at-the-market equity distribution agreement with BTIG, effective July 23, 2026. An ATM facility typically allows a listed company to sell newly issued shares periodically at prevailing market prices, providing flexibility to raise capital without completing a conventional underwritten offering.

The termination removes this specific source of equity financing from the company’s capital-management framework. Matinas BioPharma Holdings, Inc. (NYSE: MTNB) confirmed that the decision did not trigger penalties or incremental expenses, limiting the immediate financial impact associated with closing the arrangement.

MAT2203 Divestment Reshapes the Business

The move comes during a broader corporate restructuring. Matinas BioPharma Holdings, Inc. (NYSE: MTNB) previously divested MAT2203, an oral formulation developed using its lipid nanocrystal delivery platform, to privately held Azurity Pharmaceuticals. The transaction reduced the company’s direct exposure to the asset and marked a significant change in its biotechnology development strategy.

The divestment also altered the company’s operating profile. With MAT2203 no longer forming part of its core development portfolio, future financial performance will depend increasingly on the terms of its strategic transactions, remaining corporate obligations and access to adequate liquidity.

Proposed GH Power Merger Drives Strategic Pivot

Matinas BioPharma Holdings, Inc. (NYSE: MTNB) is also pursuing a proposed merger with privately held GH Power. The transaction would represent a substantial shift in strategic focus and could reshape the combined company’s assets, operations and capital requirements.

However, completion remains subject to the applicable transaction conditions and corporate approvals. Until then, the company must continue managing its existing expenses and liquidity needs independently.

Funding and Listing Risks Remain Material

The closure of the ATM facility does not itself create a financial charge, but it narrows the company’s immediate financing options through that platform. This is relevant because Matinas BioPharma Holdings, Inc. (NYSE: MTNB) continues to report operating deficits and faces listing-compliance challenges.

Its near-term financial position will therefore remain linked to cash preservation, alternative funding sources and progress on the proposed GH Power transaction. These factors remain central to evaluating the company’s restructuring and continuing operating capacity.